Volumetric laser endomicroscopy in the management of Barrett's esophagus

Arvind J. Trindade, Cadman Leggett, Kenneth J. Chang

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review The incidence of esophageal adenocarcinoma is on the rise despite widespread appreciation that the precursor lesion is Barrett's esophagus. Studies have shown that some patients known to have Barrett's esophagus develop cancer despite their enrollment in conventional endoscopic surveillance programs. This highlights the need for advanced endoscopic imaging to help identify early neoplasia and prevent its progression to esophageal cancer. Recently, a wide-field, second-generation optical coherence tomography endoscopic platform called volumetric laser endomicroscopy (VLE) was cleared by the Food and Drug Administration and made commercially available for advanced imaging in Barrett's esophagus. Recent findings The current review discusses current literature on VLE imaging in Barrett's esophagus. Based on ex-vivo studies, criteria have been established for identifying Barrett's esophagus-associated neoplasia. In addition, recent studies, case series, and case reports have demonstrated that VLE is well tolerated, efficacious, and can target neoplasia. Summary VLE is a new advanced imaging platform for Barrett's esophagus with considerable promise to target Barrett's esophagus-associated neoplasia. The following are needed to establish VLE's clinical role: studies showing incremental yield of dysplasia detection using VLE, studies to determine VLE's in-vivo diagnostic accuracy for identifying and classifying Barrett's esophagus-associated neoplasia, and studies on the cost-efficacy of VLE.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume33
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Barrett Esophagus
Lasers
Neoplasms
Esophageal Neoplasms
Optical Coherence Tomography
United States Food and Drug Administration
Adenocarcinoma
Costs and Cost Analysis
Incidence

Keywords

  • advanced imaging
  • dysplasia
  • neoplasia
  • optical coherence tomography

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Volumetric laser endomicroscopy in the management of Barrett's esophagus. / Trindade, Arvind J.; Leggett, Cadman; Chang, Kenneth J.

In: Current Opinion in Gastroenterology, Vol. 33, No. 4, 01.07.2017, p. 254-260.

Research output: Contribution to journalReview article

Trindade, Arvind J. ; Leggett, Cadman ; Chang, Kenneth J. / Volumetric laser endomicroscopy in the management of Barrett's esophagus. In: Current Opinion in Gastroenterology. 2017 ; Vol. 33, No. 4. pp. 254-260.
@article{cf8fc3c535df45ebbcbe5fca0e985bfc,
title = "Volumetric laser endomicroscopy in the management of Barrett's esophagus",
abstract = "Purpose of review The incidence of esophageal adenocarcinoma is on the rise despite widespread appreciation that the precursor lesion is Barrett's esophagus. Studies have shown that some patients known to have Barrett's esophagus develop cancer despite their enrollment in conventional endoscopic surveillance programs. This highlights the need for advanced endoscopic imaging to help identify early neoplasia and prevent its progression to esophageal cancer. Recently, a wide-field, second-generation optical coherence tomography endoscopic platform called volumetric laser endomicroscopy (VLE) was cleared by the Food and Drug Administration and made commercially available for advanced imaging in Barrett's esophagus. Recent findings The current review discusses current literature on VLE imaging in Barrett's esophagus. Based on ex-vivo studies, criteria have been established for identifying Barrett's esophagus-associated neoplasia. In addition, recent studies, case series, and case reports have demonstrated that VLE is well tolerated, efficacious, and can target neoplasia. Summary VLE is a new advanced imaging platform for Barrett's esophagus with considerable promise to target Barrett's esophagus-associated neoplasia. The following are needed to establish VLE's clinical role: studies showing incremental yield of dysplasia detection using VLE, studies to determine VLE's in-vivo diagnostic accuracy for identifying and classifying Barrett's esophagus-associated neoplasia, and studies on the cost-efficacy of VLE.",
keywords = "advanced imaging, dysplasia, neoplasia, optical coherence tomography",
author = "Trindade, {Arvind J.} and Cadman Leggett and Chang, {Kenneth J.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MOG.0000000000000366",
language = "English (US)",
volume = "33",
pages = "254--260",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Volumetric laser endomicroscopy in the management of Barrett's esophagus

AU - Trindade, Arvind J.

AU - Leggett, Cadman

AU - Chang, Kenneth J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose of review The incidence of esophageal adenocarcinoma is on the rise despite widespread appreciation that the precursor lesion is Barrett's esophagus. Studies have shown that some patients known to have Barrett's esophagus develop cancer despite their enrollment in conventional endoscopic surveillance programs. This highlights the need for advanced endoscopic imaging to help identify early neoplasia and prevent its progression to esophageal cancer. Recently, a wide-field, second-generation optical coherence tomography endoscopic platform called volumetric laser endomicroscopy (VLE) was cleared by the Food and Drug Administration and made commercially available for advanced imaging in Barrett's esophagus. Recent findings The current review discusses current literature on VLE imaging in Barrett's esophagus. Based on ex-vivo studies, criteria have been established for identifying Barrett's esophagus-associated neoplasia. In addition, recent studies, case series, and case reports have demonstrated that VLE is well tolerated, efficacious, and can target neoplasia. Summary VLE is a new advanced imaging platform for Barrett's esophagus with considerable promise to target Barrett's esophagus-associated neoplasia. The following are needed to establish VLE's clinical role: studies showing incremental yield of dysplasia detection using VLE, studies to determine VLE's in-vivo diagnostic accuracy for identifying and classifying Barrett's esophagus-associated neoplasia, and studies on the cost-efficacy of VLE.

AB - Purpose of review The incidence of esophageal adenocarcinoma is on the rise despite widespread appreciation that the precursor lesion is Barrett's esophagus. Studies have shown that some patients known to have Barrett's esophagus develop cancer despite their enrollment in conventional endoscopic surveillance programs. This highlights the need for advanced endoscopic imaging to help identify early neoplasia and prevent its progression to esophageal cancer. Recently, a wide-field, second-generation optical coherence tomography endoscopic platform called volumetric laser endomicroscopy (VLE) was cleared by the Food and Drug Administration and made commercially available for advanced imaging in Barrett's esophagus. Recent findings The current review discusses current literature on VLE imaging in Barrett's esophagus. Based on ex-vivo studies, criteria have been established for identifying Barrett's esophagus-associated neoplasia. In addition, recent studies, case series, and case reports have demonstrated that VLE is well tolerated, efficacious, and can target neoplasia. Summary VLE is a new advanced imaging platform for Barrett's esophagus with considerable promise to target Barrett's esophagus-associated neoplasia. The following are needed to establish VLE's clinical role: studies showing incremental yield of dysplasia detection using VLE, studies to determine VLE's in-vivo diagnostic accuracy for identifying and classifying Barrett's esophagus-associated neoplasia, and studies on the cost-efficacy of VLE.

KW - advanced imaging

KW - dysplasia

KW - neoplasia

KW - optical coherence tomography

UR - http://www.scopus.com/inward/record.url?scp=85017407792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017407792&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000366

DO - 10.1097/MOG.0000000000000366

M3 - Review article

C2 - 28402993

AN - SCOPUS:85017407792

VL - 33

SP - 254

EP - 260

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -